Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped This study was prematurely terminated due to sponsor decision.

Conditions

SCN8A Developmental and Epileptic Encephalopathy Syndrome

Interventions

DRUG: NBI-921352
DRUG: Placebo

Sponsor

Neurocrine Biosciences